April 1, 2025 10:55 AM EDTUpdated 03:21 PM
R&D

Com­pass Ther­a­peu­tics touts tri­al suc­cess in bil­iary tract can­cer, but more da­ta are need­ed

Lei Lei Wu

News Reporter

Com­pass Ther­a­peu­tics said Tues­day that adding its bis­pe­cif­ic an­ti­body to chemother­a­py sig­nif­i­cant­ly im­proved re­sponse rates com­pared to chemother­a­py alone in a Phase 2/3 bil­iary tract …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Q&A: John Crow­ley warns biotech is 'dan­ger­ous­ly close' to break­ing, as tar­iff threat, mar­kets bat­ter in­dus­try

Day af­ter mass FDA fir­ings, new com­mis­sion­er ad­dress­es re­main­ing staff, fo­cus­ing on 'MA­HA' vi­sion

Fir­ings sweep across FDA as for­mer lead­ers lament the gut­ting of drug agency

Roche says Ocre­vus failed Phase 3 study; Sanofi li­cens­es au­toim­mune as­set from Nurix

Ex­clu­sive: Mikael Dol­sten shares his post-Pfiz­er plans, in­clud­ing ad­vis­ing an AI uni­corn with phar­ma dreams

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times